Open dataset

Cell-therapy trials matrix: condition × cell type

The one-table answer to “how studied is it?” Registered studies on ClinicalTrials.gov per condition, split by therapy class. Snapshot 2026-08-29; regenerated from the live registry. Registration measures research activity, not effectiveness or approval.

Highlights: knee osteoarthritis is the most-trialled MSC indication (124 studies); multiple sclerosis is a near-tie between HSCT and MSC approaches (38 vs 37); androgenetic alopecia is the only tracked condition where exosome studies outnumber MSC studies (10 vs 7).

ConditionMSCMSC recruitingHSCT-familyExosomes
Knee Osteoarthritis1249104
Cirrhosis625214
Crohns Ibd526182
Stroke Recovery4571411
Spinal Cord Injury382111
Multiple Sclerosis373382
Heart Failure323131
Diabetes291141
Als292111
Alzheimers236110
Lupus234172
Erectile Dysfunction23505
Rheumatoid Arthritis222114
Parkinsons19135
Aging16135
Cerebral Palsy13181
Autism10435
Copd10421
Psoriasis10001
Long Covid9101
Muscular Dystrophy9011
Hair Loss74010
Atopic Dermatitis5003
Macular Degeneration4211
Male Infertility4121
Sma2001

Method: ClinicalTrials.gov API v2, query.cond × query.intr counts; “recruiting” uses overallStatus=RECRUITING. Reproducible via the open queries listed on our methodology page.

Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.